Smad4 Loss In Colorectal Cancer: Correlation With Recurrence, Chemoresistance, And Immune Infiltrate.

Isaac Wasserman,Lik Hang Lee,Jinru Shia,Chao Wu,Xi Chen,Jose G. Guillem,Philip B. Paty,Martin R. Weiser,Garrett M. Nash,Larissa K. Temple,Leonard Saltz,Rona Yaeger,Afsar Barlas,Katia Manova-Todorova,Efsevia Vakiani,Arthur E Elghouayel,Nancy E. Kemeny,Julio Garcia-Aguilar,Charles L. Sawyers,Jesse J. Smith
DOI: https://doi.org/10.1200/JCO.2017.35.4_suppl.587
IF: 45.3
2017-01-01
Journal of Clinical Oncology
Abstract:587Background: Few markers reliably identify colorectal cancer (CRC) patients at risk of recurrence and death. SMAD4 loss occurs in 10-20% of cases and has shown promise in identifying high-risk stage II/III patients. We examined SMAD4 status and association with clinical/pathologic features in 446 stage I-IV CRC patients at Memorial Sloan Kettering (MSK). Methods: Patients undergoing curative resection were included (1981-2010). Familial polyposis syndrome patients and those with inadequate tissue were excluded. Tissue microarrays were constructed (n=364). Immunohistochemistry for SMAD4 and mismatch repair (MMR) proteins was completed. SMAD4 nuclear stain intensity was scored (scale=0-3; 0=loss). On whole sections, MMR proteins (present or absent), tumor-infiltrating lymphocytes (TILs) and peritumoral lymphocyte aggregates (PLAs) were scored (scale=0-3). Associations between clinical/pathologic features and SMAD4 loss vs. retention were analyzed. Kaplan-Meier estimates and log-rank test were used for rec...
What problem does this paper attempt to address?